MED20

Across TCGA pan-cancer cohorts, MED20 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MED20’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MED20 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MED20 is over-expressed in tumor.

LSCC, LUAD, and HNSC are the cancer types where MED20 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MED20 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.587	<.001	9	view →
LUAD	Female	III,IV	+0.575	<.001	9	view →
HNSC	Male	IV	+0.390	<.001	8	view →
COAD	Female	II,III,IV	+0.141	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MED20–LSCC

Open the LSCC breakdown →